发明专利
JP2012092136A Use of dipeptidyl peptidase iv effector for lowering blood glucose level in mammal
审中-公开
用于降低血液中葡萄糖水平的DIPEPTIDYL PEPTIDASE IV效应
- 专利标题： Use of dipeptidyl peptidase iv effector for lowering blood glucose level in mammal
- 专利标题（中）： 用于降低血液中葡萄糖水平的DIPEPTIDYL PEPTIDASE IV效应
-
申请号： JP2011284809申请日： 2011-12-27
-
公开(公告)号： JP2012092136A公开(公告)日： 2012-05-17
- 发明人: DEMUTH HANS-ULRICH , ROSCHE FRED , SCHMIDT JOERN , PAULY ROBERT P , MCINTOSH CHRISTOPHER H S , PEDERSON RAY A
- 申请人： Prosidion Ltd , プロシディオン・リミテッドProsidion Limited
- 专利权人： Prosidion Ltd,プロシディオン・リミテッドProsidion Limited
- 当前专利权人： Prosidion Ltd,プロシディオン・リミテッドＰｒｏｓｉｄｉｏｎ Ｌｉｍｉｔｅｄ
- 优先权： DE19616486 1996-04-25
- 主分类号： A61K45/00
- IPC分类号： A61K45/00 ; C07D277/04 ; A61K31/00 ; A61K31/40 ; A61K31/401 ; A61K31/425 ; A61K31/426 ; A61K38/00 ; A61K38/46 ; A61K38/55 ; A61K39/395 ; A61P3/06 ; A61P3/10 ; A61P43/00
摘要：
PROBLEM TO BE SOLVED: To provide a diabetes therapeutic composition.SOLUTION: This invention relates to a composition for inhibiting Dipeptidyl Peptidase (DPIV or CD 26) or DPIV-like enzyme activity, which can inhibit degradation of the endogenous, or exogenously administrated, insulinotropic peptides (incretins), Gastric Inhibitory Polypeptide/Glucose-dependent Insulinotropic Polypeptide 1-42 (GIP) and Glucagon-like Peptide-1 7-36 amide (GLP-1) (or analogs of these peptides). As a consequence of the enhanced stability of the endogenous, or exogenously administered, incretins or their analogs, their insulinotropic effects are enhanced, resulting in a potentate stimulation of insulin secretion from the pancreatic islets of Langerhans, and more rapid removal of glucose from the blood. In the composition, the inhibitor for inhibiting enzyme activity is alanyl pyrrolidide or aminoacyl thiazolidide.
信息查询
